Larry Biscotti Joins Sensus Healthcare’s Board of Directors

Sensus Healthcare Inc. has appointed Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six directors, four of whom are independent directors.

“Larry brings to the Sensus Board a wealth of skills, value and complementary experiences. Over the course of his career, he has led multibillion-dollar P&Ls, introduced innovative cancer treatment technologies, built and scaled commercial teams and expanded businesses globally through strategic partnerships and distribution agreements,” Sensus Healthcare Chairman/CEO Joe Sardano said. “His integrity, judgment, and commitment to improving patient outcomes fit well with our culture and mission. I’ve had the privilege of working with Larry throughout my career and know firsthand the leadership and insight he brings. We are pleased to welcome Larry to our board as we expand the reach of our SRT technology and execute on our long-term vision.”

Biscotti has more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share, and launching advanced imaging and oncology technologies. He currently serves as president, Imaging, for the U.S. and Canada at GE HealthCare, where he is responsible for the company’s largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Medicine, and CTI Molecular Imaging, providing a strong foundation in imaging, oncology, and radiation therapy technologies.

Biscotti earned an MBA from Pepperdine University and a bachelor of science degree from Cornell University. He is an alumnus of Harvard Business School’s Program for Leadership Development.

“I am honored to join the Board of Directors of Sensus Healthcare at a time when patient-centered, non-invasive treatments are becoming increasingly important for a variety of conditions. The company’s commitment to innovation, clinical excellence and improving patient outcomes strongly aligns with my own personal values and professional experiences. I look forward to supporting Sensus’ continued growth and impact for patients and clinicians,” Biscotti stated.

Sensus Healthcare develops and delivers non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to various clinical settings.